Advanced search×

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

David T DT Felson, Josef S JS Smolen, George G Wells, Bin B Zhang, Lilian H D LH van Tuyl, Julia J Funovits, Daniel D Aletaha, Cornelia F CF Allaart, Joan J Bathon, Stefano S Bombardieri, Peter P Brooks, Andrew A Brown, Marco M Matucci-Cerinic, Hyon H Choi, Bernard B Combe, Maarten M de Wit, Maxime M Dougados, Paul P Emery, Daniel D Furst, Juan J Gomez-Reino, Gillian G Hawker, Edward E Keystone, Dinesh D Khanna, John J Kirwan, Tore K TK Kvien, Robert R Landewé, Joachim J Listing, Kaleb K Michaud, Emilio E Martin-Mola, Pamela P Montie, Theodore T Pincus, Pamela P Richards, Jeffrey N JN Siegel, Lee S LS Simon, Tuulikki T Sokka, Vibeke V Strand, Peter P Tugwell, Alan A Tyndall, Desirée D van der Heijde, Suzan S Verstappen, Barbara B White, Frederick F Wolfe, Angela A Zink, Maarten M Boers, and and

Arthritis Rheum 63(3):573-86 (2011) PMID 21294106 PMCID PMC3115717

Remission in rheumatoid arthritis (RA) is an increasingly attainable goal, but there is no widely used definition of remission that is stringent but achievable and could be applied uniformly as an outcome measure in clinical trials. This work was undertaken to develop such a definition.

DOI: 10.1002/art.30129
Version: za2963e q8za2 q8zb2 q8zc3 q8zd9 q8ze8 q8zf0 q8zg7
View PDF

Similar articles you may find interesting…

  1. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of ...
    Jean-Pascal Machiels, Somasundaram Subramanian, ... Paul M J Clement

    Lancet Oncol 12(4):333-43 (2011) PMID 21377930

    We randomly allocated 191 (67%) of 286 eligible patients to the zalutumumab group and 95 (33%) to the control group. Median overall survival was 6·7 months (95% CI 5·8-7·0) in the zalutumumab group and 5·2 months (4·1-6·4) in the control group (hazard ratio [HR] for death, stratified by WHO pe...
  2. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006.
    Karen H KH Costenbader, Amrita A Desai, ... Wolfgang C WC Winkelmayer

    Arthritis Rheum 63(6):1681-8 (2011) PMID 21445962

    This study was undertaken to investigate whether recent advances in lupus nephritis treatment have led to changes in the incidence of end-stage renal disease (ESRD) secondary to lupus nephritis, or in the characteristics, treatments, and outcomes of patients with lupus nephritis ESRD.
    View PDF
  3. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
    Christian C Hampp, Teresa L TL Kauf, ... Almut G AG Winterstein

    Arch Pediatr Adolesc Med 165(6):498-505 (2011) PMID 21300647

    The cost of immunoprophylaxis with palivizumab far exceeded the economic benefit of preventing hospitalizations, even in infants at highest risk for RSV infection....